# Effects of Canagliflozin on Intravascular Volume and Hemodynamics

> **NCT03190798** · PHASE4 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Type2 Diabetes Mellitus
- Cardiovascular Diseases

## Interventions

- **DRUG:** Canagliflozin 300mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03190798
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-01
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study has been withdrawn from IRB review pending IND revision
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190798, "Effects of Canagliflozin on Intravascular Volume and Hemodynamics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03190798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*